NCT05634525View on ClinicalTrials.gov

Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients

PHASE1WithdrawnINTERVENTIONAL

0

Timeline

Start Date

May 3, 2023

Primary Completion Date

July 21, 2025

Study Completion Date

July 21, 2025

Conditions

Metastatic Pancreatic Cancer

Interventions

DRUG

MRTX849

Given By PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Mirati Therapeutics Inc.

All Listed Sponsors

collaborator

Mirati Therapeutics Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT05634525 - Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients | Biotech Hunter | Biotech Hunter